Lunit Highlights AI's Role in Advancing Precision Oncology at ASCO 2025 with 12 Studies

Lunit will present multiple studies at ASCO 2025 highlighting the use of AI in cancer diagnostics and treatment, including AI models for predicting CLDN18.2 expression in gastric cancer and PD-L1 expression in lung cancer. One study suggests AI-based CLDN18.2 prediction combined with immune phenotype analysis could guide first-line gastric cancer treatment decisions, potentially reducing the need for IHC tests. These presentations aim to demonstrate AI's potential to improve treatment selection and uncover opportunities for patients who might otherwise be overlooked.

Analysis

Lunit (328130.KQ) is set to feature prominently at ASCO 2025, presenting twelve studies that underscore its advancements in applying artificial intelligence to cancer diagnostics and personalized treatment. A notable study introduces an AI model for predicting CLDN18.2 expression in gastric cancer, achieving AUROCs over 0.751, which, combined with AI-driven immune phenotype analysis from H&E slides, offers a potential pathway to guide first-line treatment decisions and reduce the need for costlier, time-consuming immunohistochemistry (IHC) tests. Other highlighted research includes AI-powered PD-L1 evaluation in lung cancer and HER2 scoring in biliary tract cancer, reinforcing Lunit's objective to transform AI into a clinically reliable tool for enhancing treatment selection and uncovering therapeutic opportunities for patients. These developments build upon Lunit's established presence, with its FDA-cleared Lunit INSIGHT suite already utilized in over 4,800 medical institutions across more than 55 countries, indicating a strong pathway for the adoption of new AI-driven diagnostic solutions. The breadth of research, including subcellular profiling and tumor microenvironment analysis, signals Lunit's commitment to deepening the clinical utility and precision of AI in oncology.

Key Decisions for Investors

• Investors should monitor the reception and detailed findings from Lunit's ASCO 2025 presentations, as positive clinical validation could significantly bolster the company's growth trajectory and market positioning in AI-driven diagnostics.
• The potential for Lunit's AI models, such as the CLDN18.2 predictor, to streamline diagnostic processes and reduce reliance on traditional methods like IHC, presents a key long-term value driver that warrants close observation for adoption rates and clinical impact.
• Given Lunit's existing global footprint and FDA-cleared products, evaluate the company's strategy and execution in commercializing these novel AI applications, as successful integration could lead to new revenue streams and enhanced competitive advantages in the rapidly evolving oncology market.